Bristol-Myers Settles Two Patent Suits on Blockbuster Sprycel

Bristol-Myers Squibb had claimed that generic versions of Sprycel proposed by Dr. Reddy’s and Lupin infringe three patents for the blockbuster leukemia drug.

• No details of settlements provided in stipulations and orders of dismissal, filed Wednesday but not yet approved in Lupin case and approved Thursday in Dr. Reddy’s case, both in federal court in Trenton, New Jersey
• Two of the patents are listed in FDA’s Orange Book for Sprycel and expire in August 2025 and September 2026
• Sprycel had U.S. sales of $1.295 billion in 2020, 8.7% higher than in 2019: data compiled by Bloomberg
• CASES: Bristol-Myers Squibb Co. ...